Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will launch profits outcomes for its 4th quarter, before the opening bell on Friday, Jan. 30.
Experts anticipate the Tarrytown, New York-based business to report quarterly profits at $10.74 per share, below $12.07 per share in the year-ago duration. The agreement price quote for Regeneron Pharmaceuticals’ quarterly profits is $3.79 billion, versus $3.79 billion a year previously, according to information from Benzinga Pro.
On Dec. 1, Regeneron Pharmaceuticals and Tessera Therapies, Inc., revealed an international partnership to establish and advertise TSRA-196.
Regeneron Pharmaceuticals shares fell 0.2% to close at $749.44 on Thursday.
Benzinga readers can access the current expert scores on the Expert Stock Scores page. Readers can arrange by stock ticker, business name, expert company, ranking modification or other variables.
Let’s take a look at how Benzinga’s most-accurate experts have actually ranked the business in the current duration.
Thinking about purchasing REGN stock? Here’s what experts believe:
Image by means of Shutterstock
Market News and Data gave you by Benzinga APIs